Roche seals deal for Genentech at $95 a share - FierceBiotech: "After eight months of bickering, Roche finally agreed to pay Genentech shareholders $46.8 billion--or $95 a share--for the 44 percent of the biotech giant it doesn't already own. And a special committee at Genentech has signed off on the deal and recommended it to shareholders."
American tax payers built Genentech. Now it is owned by a swiss company with little reason to support the US.
What happens when Lenovo buys Microsoft?
Saturday, March 14, 2009
span.fullpost {display:inline;}
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment